Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics’ AMTAGVITM (lifileucel) for the treatment of patients with advanced melanoma in the second line treatment setting.
100,000 Americans Estimated to be Diagnosed with Invasive Melanoma in 2024
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for...
Where Innovation Meets Impact: MRA 2023 Annual Report
MRA is a world leader in advancing transformational science that has caused paradigm shifts in what it means to be diagnosed with and treated for melanoma. The innovative research we support isn’t just changing science — it’s giving patients more treatment options that translate to longer, fuller lives.
New Research Alert: Melanoma and Microbiota: Current Understanding and Future Directions
A perspective article summarizing the field’s current knowledge on how the gut microbiota affects melanoma response to immunotherapy, and how this knowledge can be used to improve patient outcomes was recently published in the journal Cancer Cell.
Clinical Trials to Watch: December 2023
Treatment of advanced melanoma has dramatically improved over the past decade with 16 new therapies approved by the Food and Drug Administration (FDA). Even with these treatment advances, 50% of patients with advanced melanoma will either not respond to any of these treatments or their disease will progress creating a...
Registration Now Open: MRA's 2024 Patient Forum
Registration for MRA's Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on Wednesday, February 21, is now open. Register now to hear from leading experts in the melanoma field and have the opportunity to ask questions, discuss, and network with other people who are going through their own melanoma journey.
A Message from Our CEO on Veterans Day
On this Veterans Day, we want to express our sincere gratitude and appreciation for the brave individuals who have served and sacrificed for our country. We also want to use today to raise awareness about the unique challenges faced by veterans when it comes to increased risk of developing melanoma,...
Melanoma Risk in the Military Community
By Renee Orcione, MRA Digital Engagement & Communications Manager | 9 November 2023 In News, Prevention, Science, Treatment
Ahead of Veterans Day, the Melanoma Research Alliance (MRA) wishes to recognize the brave individuals who have served and sacrificed for our country. As the largest private nonprofit funder of melanoma research worldwide, we are keenly aware of the important intersection between military service and melanoma.
What Veteran's Day Means to the MRA Team
In observation of Veteran's Day - November 11 - we asked the MRA team to create short videos explaining what the day means for them and what they want Veterans and other military personnel to know about their risk for melanoma, other skin cancers, and the importance of sun safety.
What Melanoma Patients Need to Know about Hepzato Kit
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 October 2023 In News, Science, Treatment
You may have heard of Hepzato Kit, also known as Liver-Directed Melphalan, the first liver-directed therapy available for patients with metastatic uveal melanoma who have liver metastases that cannot be surgically removed.